STOCK TITAN

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

China Pharma Holdings (NYSE American: CPHI) has announced a 1-for-10 reverse stock split effective April 15, 2025. The company's Board of Directors authorized a reverse split ratio between 1:10 and 1:20 on October 22, 2024, which was approved by stockholders on December 22, 2024. The Board ultimately fixed the ratio at 1:10 on March 26, 2025.

Under this arrangement, every 10 shares of CPHI's issued and outstanding common stock will be automatically converted into one share. The stock will continue trading on NYSE American under the symbol 'CPHI' with a new CUSIP number: 16941T 401. Any fractional shares resulting from the split will be rounded up to the next whole number, ensuring that stockholders' percentage interests remain unchanged except for minor adjustments due to fractional share treatment.

China Pharma Holdings (NYSE American: CPHI) ha annunciato un raggruppamento azionario inverso 1-per-10 che entrerà in vigore il 15 aprile 2025. Il Consiglio di Amministrazione della società ha autorizzato un rapporto di raggruppamento tra 1:10 e 1:20 il 22 ottobre 2024, approvato dagli azionisti il 22 dicembre 2024. Il Consiglio ha fissato infine il rapporto a 1:10 il 26 marzo 2025.

Con questo accordo, ogni 10 azioni ordinarie emesse e in circolazione di CPHI saranno automaticamente convertite in una sola azione. Le azioni continueranno a essere negoziate su NYSE American con il simbolo 'CPHI' e un nuovo numero CUSIP: 16941T 401. Eventuali frazioni di azioni risultanti dal raggruppamento saranno arrotondate al numero intero successivo, garantendo che gli interessi percentuali degli azionisti rimangano invariati, eccetto per lievi aggiustamenti dovuti al trattamento delle frazioni di azioni.

China Pharma Holdings (NYSE American: CPHI) ha anunciado un split inverso de acciones 1 por 10 que entrará en vigor el 15 de abril de 2025. La Junta Directiva de la empresa autorizó una relación de split entre 1:10 y 1:20 el 22 de octubre de 2024, que fue aprobada por los accionistas el 22 de diciembre de 2024. La Junta finalmente fijó la relación en 1:10 el 26 de marzo de 2025.

Según este acuerdo, cada 10 acciones ordinarias emitidas y en circulación de CPHI se convertirán automáticamente en una acción. Las acciones continuarán cotizando en NYSE American bajo el símbolo 'CPHI' con un nuevo número CUSIP: 16941T 401. Cualquier acción fraccionaria resultante del split se redondeará al siguiente número entero, asegurando que los intereses porcentuales de los accionistas permanezcan sin cambios, excepto por pequeños ajustes debido al tratamiento de acciones fraccionarias.

China Pharma Holdings (NYSE American: CPHI)는 2025년 4월 15일부터 시행되는 1대 10 비율의 주식 병합을 발표했습니다. 회사 이사회는 2024년 10월 22일 1:10에서 1:20 사이의 비율을 승인했으며, 이는 2024년 12월 22일 주주들에 의해 승인되었습니다. 이사회는 최종적으로 2025년 3월 26일 비율을 1:10으로 확정했습니다.

이 협정에 따라 CPHI의 발행 및 유통 주식 10주는 자동으로 1주로 전환됩니다. 주식은 'CPHI' 기호로 NYSE American에서 계속 거래되며, 새로운 CUSIP 번호는 16941T 401입니다. 병합으로 인해 발생하는 분할 주식은 다음 정수로 반올림되어 주주들의 비율이 변경되지 않도록 보장합니다. 단, 분할 주식 처리로 인한 소규모 조정은 있을 수 있습니다.

China Pharma Holdings (NYSE American: CPHI) a annoncé un rachat d'actions inversé 1 pour 10 qui prendra effet le 15 avril 2025. Le Conseil d'Administration de l'entreprise a autorisé un ratio de rachat entre 1:10 et 1:20 le 22 octobre 2024, qui a été approuvé par les actionnaires le 22 décembre 2024. Le Conseil a finalement fixé le ratio à 1:10 le 26 mars 2025.

Dans le cadre de cet arrangement, chaque 10 actions ordinaires émises et en circulation de CPHI seront automatiquement converties en une seule action. Les actions continueront d'être négociées sur NYSE American sous le symbole 'CPHI' avec un nouveau numéro CUSIP : 16941T 401. Toute action fractionnaire résultant du rachat sera arrondie au nombre entier supérieur, garantissant que les intérêts en pourcentage des actionnaires restent inchangés, sauf pour de légers ajustements dus au traitement des actions fractionnaires.

China Pharma Holdings (NYSE American: CPHI) hat einen 1-zu-10 Rückwärtssplit angekündigt, der am 15. April 2025 in Kraft tritt. Der Vorstand des Unternehmens genehmigte am 22. Oktober 2024 ein Rücksplit-Verhältnis zwischen 1:10 und 1:20, das am 22. Dezember 2024 von den Aktionären genehmigt wurde. Der Vorstand legte schließlich am 26. März 2025 das Verhältnis auf 1:10 fest.

Im Rahmen dieser Regelung werden jeweils 10 ausgegebene und im Umlauf befindliche Stammaktien von CPHI automatisch in eine Aktie umgewandelt. Die Aktien werden weiterhin an der NYSE American unter dem Symbol 'CPHI' gehandelt, mit einer neuen CUSIP-Nummer: 16941T 401. Alle durch den Split entstehenden Bruchstücke werden auf die nächste ganze Zahl aufgerundet, sodass die prozentualen Interessen der Aktionäre unverändert bleiben, abgesehen von geringfügigen Anpassungen aufgrund der Behandlung von Bruchstücken.

Positive
  • Higher nominal share price could attract institutional investors
  • Maintenance of NYSE American listing status
Negative
  • Implementation of reverse stock split typically indicates previous stock price decline
  • Potential risk of delisting concerns, as reverse splits are often used to maintain exchange listing requirements

HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401.

The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by the Company's stockholders through the Annual Meeting for the fiscal year ended on December 31, 2023, which was held on December 22, 2024. The Board fixed a ratio of 1:10 on March 26, 2025.

Upon the effectiveness of the reverse stock split, every 10 shares of the Company's issued and outstanding common stock will automatically be converted into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announces-1-for-10-reverse-stock-split-302421049.html

SOURCE China Pharma Holdings, Inc.

FAQ

When will China Pharma Holdings (CPHI) implement its reverse stock split?

CPHI will implement the 1-for-10 reverse stock split on April 15, 2025, with trading beginning on a split-adjusted basis at market open.

What happens to fractional shares in CPHI's reverse stock split?

Fractional shares resulting from the 1-for-10 split will be rounded up to the next whole number.

Will CPHI's reverse stock split affect shareholders' ownership percentage?

No, the reverse split will not alter stockholders' percentage interest in the company's outstanding common stock, except for minor adjustments from fractional shares.

What is the new CUSIP number for CPHI after the reverse split?

The new CUSIP number following the reverse stock split is 16941T 401.
China Pharma

NYSE:CPHI

CPHI Rankings

CPHI Latest News

CPHI Stock Data

4.44M
9.38M
51.28%
0.9%
2.43%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
China
HAINAN PROVINCE